Varicosity
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Clinical and Genetic Determinants of Varicose Veins.
|
30566020 |
2018 |
Tryptophan measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic basis for plasma amino acid concentrations based on absolute quantification: a genome-wide association study in the Japanese population.
|
30659259 |
2019 |
Short stepped shuffling gait
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Reduced concentration span
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
PRKAR1B-related neurodegenerative dementia with intermediate filaments
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology.
|
24722252 |
2014 |
PRKAR1B-related neurodegenerative dementia with intermediate filaments
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort.
|
25108559 |
2014 |
Primary pigmented nodular adrenocortical disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Somatic and germ line inactivating mutations of PRKAR1 (regulatory subunit R1A of PKA) can be observed in patient with isolated primary pigmented nodular adrenocortical disease (PPNAD) and AA responsible for ACS.
|
12530696 |
2002 |
Primary Pigmented Nodular Adrenal Dysplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Somatic and germ line inactivating mutations of PRKAR1 (regulatory subunit R1A of PKA) can be observed in patient with isolated primary pigmented nodular adrenocortical disease (PPNAD) and AA responsible for ACS.
|
12530696 |
2002 |
Presenile dementia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
With this study, we aimed to investigate the mutation frequency of the major AD and FTD genes and the PRKAR1B gene in a well-defined Dutch cohort of patients with early onset dementia.
|
25108559 |
2014 |
Postural instability
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Pick Disease of the Brain
|
0.010 |
Biomarker
|
disease |
BEFREE |
Screening of PRKAR1B in 138 patients with Parkinson's disease and 56 patients with frontotemporal dementia did not identify additional novel pathogenic mutations.
|
24722252 |
2014 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Screening of PRKAR1B in 138 patients with Parkinson's disease and 56 patients with frontotemporal dementia did not identify additional novel pathogenic mutations.
|
24722252 |
2014 |
Neurodegenerative Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology.
|
24722252 |
2014 |
Muscular stiffness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Motor deterioration
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Memory Impairment, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Memory Impairment, CTCAE 3.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Memory impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Language Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Inertia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Inappropriate behavior
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Impaired visuospatial constructive cognition
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|